Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Expression of TGF-β Signaling Genes in the Normal, Premalignant, and Malignant Human Trophoblast: Loss of Smad3 in Choriocarcinoma Cells

Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells

Restoration of TGF-beta regulation of plasminogen activator inhibitor-1 in Smad3-restituted human choriocarcinoma cells.

Restoration of TGF-β regulation of plasminogen activator inhibitor-1 in Smad3-restituted human choriocarcinoma cells

Expression of Smad3 mRNA and Smad7 mRNA of TGF-β1 in keloid-derived fibroblasts

Expression of TGF-beta Signaling Proteins in Normal Placenta and Gestational Trophoblastic Disease.

Transforming Growth Factor Β1 Promotes Invasion of Human JEG-3 Trophoblast Cells Via TGF-β/Smad3 Signaling Pathway

Transforming growth factor β1 promotes invasion of human JEG-3 trophoblast cells via TGF-β/Smad3 signaling pathway.

Expression of TGF-β1, TβRII and Smad4 in Colorectal Carcinoma

Gdf8 Promotes The Cell Invasiveness In Human Trophoblasts By Upregulating The Expression Of Follistatin-Like 3 Through The Alk5-Smad2/3 Signaling Pathway

Decreased Levels Of Active Smad2 Correlate With Poor Prognosis In Gastric Cancer

Resistance to transforming growth factor–beta occurs in the presence of normal Smad activation

Overexpression of trophoblastic stem cell transcription factor,forkhead boxD3,contributes to malignancy of human choriocarcinoma JAR cells

Functional Characterization of Transforming Growth Factor Β Signaling in Smad2- and Smad3-deficient Fibroblasts*

TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Expression Of Tgf-Beta Related Smad Proteins In Human Epithelial Skin Tumors

Expression of Smad in breast cancer cells and normal breast epithelium cells and significance

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

Dual Effect of Transforming Growth Factor Beta1 on Cell Adhesion and Invasion in Human Placenta Trophoblast Cells.

Expression of Smad proteins in human colorectal cancer.